To report a case of gangrene as a rare but serious adverse event following treatment with Sn-117m-DTPA in a patient with extensive skeletal metastases from castration-resistant prostate cancer.
Key Findings:
Gangrene occurred 24 days after a single dose of Sn-117m-DTPA.
Patient experienced significant pain relief from skeletal metastases despite the adverse events, indicating a complex relationship between treatment efficacy and safety.
Gangrene was complicated by leukopenia and sepsis from aspiration pneumonia.
Interpretation:
Gangrene is a rare but serious adverse event that may occur after radiopharmaceutical treatment, highlighting the need for prompt intervention and vigilant monitoring of skin integrity in clinical practice.
Limitations:
No autopsy was performed to confirm the cause of death, limiting understanding of the event's etiology.
Limited understanding of the natural history and mechanisms of radiopharmaceutical-related adverse events.
Conclusion:
The case underscores the importance of recognizing and addressing skin integrity issues in patients receiving radiopharmaceuticals, as timely intervention is critical for patient outcomes.
